Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR T-cells in B-cell Leukemia
NCT04100187Phase 1Unknown
- Sponsor
- Beijing Kecellitics Biotech Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19-CAR (Kecellitics Biotech) in B-cell leukemia (BCL), sponsored by Beijing Kecellitics Biotech Co., Ltd. Primary endpoints: Adverse events of each patient at 3 years, Survival time of Anti-CD19 CAR T cells in vivo at 3 years and 2 more. Status: unknown.
02
Drugs
anti-CD19-CAR (Kecellitics Biotech)
03
Conditions
B-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT04100187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100187.